Amneal CEO: Changes At Teva, Sandoz And Viatris Give Us Room To Grow
Chirag Patel Talks International Expansion And Focus On Complex Generics
Executive Summary
Amid upheaval for leading industry players Sandoz, Teva and Viatris, Amneal sees room to grow both in its home market and internationally, according to co-CEO Chirag Patel.
You may also be interested in...
Differentiation Is Mantra As Amneal Targets $1bn By 2030 From Non-US Geographies
As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.
Five Things Facing Teva’s New CEO Richard Francis
With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.
Viatris To Shed OTC, APIs And Women’s Health As Biocon Deal Nears Completion
Viatris has marked an important inflection point in its short life, announcing several more planned divestitures alongside the proposed acquisition of a pair of eyecare companies for up to $750m in cash.